Form 4: 89bio COO Disposes Shares in Roche Merger Completion

89bio, Inc. Chief Operating Officer Sarena Francis Willard disposed of common stock and stock options following the completion of the company's merger with Roche Holdings, Inc.

Summary

• 89bio, Inc. completed its merger with Roche Holdings, Inc. and Bluefin Merger Subsidiary, Inc. on October 30, 2025, becoming a wholly-owned subsidiary of Roche.
• The tender offer for all outstanding shares of 89bio common stock was completed at an offer price of $14.50 per share in cash (the 'Closing Amount') plus one non-tradeable contingent value right (CVR).
• Each CVR represents the right to receive certain contingent payments of up to an aggregate amount of $6.00 per share upon the achievement of specified milestones.
• Sarena Francis Willard, Chief Operating Officer, disposed of 75,310 shares of common stock, which included 1,709 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on October 22, 2025.
• Outstanding stock options held by the Reporting Person, including 350,000 options with an exercise price of $8.39 and 215,000 options with an exercise price of $9.6, became fully vested and were cancelled.
• These options were converted into the right to receive cash (Closing Amount minus exercise price) plus one CVR per share, or only CVRs and contingent cash payments for 'Out of the Money Options' (exercise price > $14.50 but < $20.50).
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment.
• Following these transactions, the Reporting Person beneficially owns 0 shares of common stock and 0 derivative securities in the now private entity.

Sentiment

Score: 7

Explanation: The completion of the merger provides a clear exit for shareholders with a defined cash payment and potential upside from CVRs. While the company ceases to be independent, the transaction provides liquidity and a premium for shareholders, generally a positive outcome for investors.

Positives

• The merger provides 89bio shareholders with a definitive cash payment of $14.50 per share upfront.
• Shareholders also receive potential additional value of up to $6.00 per share through Contingent Value Rights (CVRs) tied to future milestones.
• All outstanding restricted stock units, performance-based restricted stock units, and stock options became fully vested and were converted into the right to receive the Offer Price or Option Consideration, providing liquidity to employees.

Negatives

• 89bio, Inc. ceases to be an independent publicly traded company, removing its stock from public exchanges.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment, resulting in a loss for holders of those specific options.

Risks

• The full value of the CVRs (up to $6.00 per share) is contingent upon the achievement of specified milestones, meaning the total consideration received by shareholders could be less than $20.50 per share.
• The CVRs are non-tradeable, limiting liquidity and the ability for holders to realize their value before milestones are met.

Future Outlook

89bio, Inc. is now a wholly-owned subsidiary of Roche Holdings, Inc., and its independent public operations and future outlook are no longer applicable. The future value for former shareholders holding CVRs depends on the achievement of specified milestones.

Industry Context

This acquisition reflects a continuing trend in the biotechnology and pharmaceutical sectors where larger, established companies acquire smaller biotech firms to expand their pipelines and gain access to innovative therapies. The use of Contingent Value Rights (CVRs) is a common mechanism in such deals to bridge valuation gaps and share future development risks and rewards.

Comparison to Industry Standards

• The deal structure, combining an upfront cash payment with contingent value rights (CVRs), is a standard approach in biotech acquisitions, similar to deals like Bristol-Myers Squibb's acquisition of MyoKardia or Gilead Sciences' acquisition of Immunomedics, where CVRs were used to provide additional value tied to clinical or regulatory milestones.
• The offer price of $14.50 cash plus up to $6.00 in CVRs provides a total potential value of $20.50, which can be compared to recent biotech acquisition premiums, though specific comparable projects or companies are not detailed in this filing.

Stakeholder Impact

• Shareholders: Received $14.50 per share in cash and one CVR per share, providing immediate liquidity and potential future payments.
• Employees (including Reporting Person): Stock options and restricted stock units vested and were converted into cash and CVRs, providing a financial benefit from the acquisition.

Next Steps

• Former 89bio shareholders holding CVRs will await potential future payments upon the achievement of specified milestones as per the CVR Agreement.

Key Dates

Keywords

89bio, ETNB, Roche Holdings, Merger, Tender Offer, Contingent Value Right, CVR, Form 4, Insider Transaction, Acquisition, Biotechnology, Pharmaceutical